The monoclonal antibody 266-6K1 recognizes human myeloperoxidase (MPO), an ~135 glycoprotein
expressed in all cells of the myeloid linage. MPO functions as an α2β2 heteromultimer consisting of
two heavy (α) and two light (β) chains of 55 and 15 kDa respectively. MPO is abundantly present in
azurophilic granules of polymorphonuclear neutrophils (PMNs). It is an important enzyme used during
phagocytic lysis of engulfed foreign particles which takes part in the defense of the organism through
production of hypochlorous acid (HOCl), a potent oxidant. In the stimulated PMN, MPO catalyzes the
production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic
intermediates that greatly enhance PMN microbicidal activity. Upon activation of neutrophils, MPO can
be rapidly released and as such useful in body fluids as marker for inflammatory status.
Involvement of MPO has been described in numerous diseases such as atherosclerosis, lung cancer,
Alzheimer’s disease, inflammatory bowel disease and multiple sclerosis. Autoimmune antibodies to
MPO (so called ANCA) are involved in Wegener’s disease. Since the discovery of MPO deficiency,
initially regarded as rare and restricted to patients suffering from severe infections, MPO has attracted
more clinical attention.
Immuno assays, Western blot
W: Samples were subjected to SDS-PAGE and transferred to PVDF membrane (Ref.1).
IA: The antibody can be used as coat and detector.
For Western blotting and immunohistology dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.
Neutrophils, HL-60 cells